University of New Mexico Cancer Center Support

服务于辽阔美丽的地理区域，具有丰富的多元文化和多民族多样性，巨大的科学 机遇，挑战健康和社会经济差异，新墨西哥大学癌症中心及其 联盟机构-洛夫莱斯呼吸研究所、洛斯阿拉莫斯国家实验室和桑迪亚国家实验室 实验室-独一无二地准备在癌症研究方面取得重大进展并为我们的社区和 我们的国家。作为方圆500英里内唯一的NCI癌症中心，UNM癌症的特点 中心包括：它所服务的多种族和多文化人口-主要是西班牙裔/拉丁裔，美国印第安人， 和非西班牙裔白人--他们的癌症发病率、死亡率和差异模式截然不同； 整合工程、生物技术、纳米技术、放射性同位素、药物发现、 将成像和高性能计算纳入其研究计划和共享资源；以及广泛的 它为提供癌症护理而建立的全州范围的外展网络，为以社区为基础的文化相宜的社区 教育和参与性研究，以及社区肿瘤学家参与新墨西哥州癌症中心临床 审判。自2005年NCI P30 CCSG的上一次审查以来，该中心的年度同行评议研究资金 总成本增加了40%，超过4680万美元，而来自NCI的年度资金增加了30%，超过13.8美元 百万美元。中心117个成员之间的方案内和方案间协作有 在4个研究项目中，每个项目的增长幅度从20%到48%不等：癌症人口科学， 癌症生物学和生物技术、血液恶性肿瘤和女性癌症。癌症中心成员 领导美国国立卫生研究院资助的9个高通量目标筛选和分子发现路线图中心之一 [U54MH084690]，NIH资助的10个国家系统生物学中心之一(P50GM085273)，4个NSF/NCI之一 纳米科学和微系统综合培训中心(DGE0504276)，20个LLS专业中心之一 白血病研究中心(LLS SCOR 7388-06)和跨学科HPV预防中心(NIH U19AI084081)。至 确保所有新墨西哥人都能获得出色的癌症诊断和治疗，新墨西哥州癌症中心 新开业面积206,432平方米。FT，9,000万美元，癌症治疗和临床研究设施，2009年8月， 是新墨西哥州立大学全州癌症护理网络的枢纽。在与西门子的合作下，这个新设施包括 一个放射性同位素生产实验室和实验放射性药物，这将加速该中心的研究 程序。从2009年7月1日至2009年7月1日，新墨西哥大学癌症中心继续向服务不足和没有保险的人提供服务 在该中心接受治疗的2640名新诊断患者中，有443人(17%)参加了治疗性临床试验；51% 这些患者是西班牙裔或美国印第安人。社区附属机构又为UNM积累了101名患者 治疗试验。此外，该中心在这段时间内有845项非干预方案的应计项目。整体而言 UNM癌症中心的目标是：1)在我们的实验室、诊所进行杰出的跨学科研究 以及建立在我们独特的科学和区域优势基础上的多民族和多文化社区；2)减少 发现遗传、环境、社会和行为因素对癌症发病率和死亡率的负担 这导致了美国西南部人民的癌症模式和癌症差异；3) 将我们的科学发现转化为新的诊断、筛查、预防和治疗工具和临床试验； 以及4)为所有新墨西哥人提供杰出的癌症治疗和临床试验。

Serving a vast geographic region of great beauty, with rich multicultural and multiethnic diversity, tremendous scientific opportunity, and challenging health and socioeconomic disparities, the University of New Mexico Cancer Center and its consortium institutions - Lovelace Respiratory Research Institute, Los Alamos National Laboratory, and Sandia National Laboratories - are uniquely poised to make significant advances in cancer research and to serve our communities and our nation. As the only NCI Cancer Center within a 500 mile radius, the special characteristics of the UNM Cancer Center include: the multiethnic and multicultural populations that it serves - primarily Hispanic/Latino, American Indian, and non-Hispanic White - with their strikingly different patterns of cancer incidence, mortality, and disparity; the integration of regional scientific strengths in engineering, biotechnology, nanotechnology, radioisotopes, drug discovery, imaging, and high performance computing into its Research Programs and Shared Resources; and the extensive statewide outreach networks it has built for the delivery of cancer care, for culturally appropriate community-based education and participatory research, and for the participation of community oncologists in UNM Cancer Center clinical trials. Since the previous NCI P30 CCSG review in 2005, the Center's annual peer-reviewed research funding has increased 40% to over $46.8 million dollars in total costs, while annual funding from NCI increased 30% to over $13.8 million dollars. Intra-programmatic and inter-programmatic collaborations among the 117 members of the Center have increased markedly and range from 20-48% in each of the 4 Research Programs: Cancer Population Sciences, Cancer Biology and Biotechnology, Hematologic Malignancies, and Women's Cancers. Cancer Center members lead one of 9 NIH-funded Roadmap Centers for High Throughput Target Screening and Molecular Discovery {U54MH084690), one of 10 NIH-funded National Centers for Systems Biology (P50GM085273), one of 4 NSF/NCI Centers for Integrative Nanoscience and Microsystems Training (DGE0504276), one of 20 LLS Specialized Centers ol Leukemia Research (LLS SCOR 7388-06), and an Interdisciplinary HPV Prevention Center (NIH U19AI084081). To assure that all New Mexicans have access to outstanding cancer diagnosis and treatment, the UNM Cancer Center opened its new 206,432 sq. ft., $90 million, Cancer Treatment and Clinical Research Facility in August 2009 which serves as the hub of the UNM Statewide Cancer Care Network. In collaboration with Siemens, this new facility contains a radioisotope production laboratory and experimental radiopharmacy, which will accelerate the Center's research programs. From 7/1/08-7/1/09, while maintaining its mission to the underserved and uninsured, the UNM Cancer Center accrued 443 (17%) of the 2640 newly diagnosed patients treated at the Center to therapeutic clinical trials; 51% of these patients were Hispanic or American Indian. Community affiliates accrued another 101 patients to UNM therapeutic trials. In addition, the Center had 845 accruals to non-intervention protocols in this time period. The overall goals of the UNM Cancer Center are to: 1) conduct outstanding transdisciplinary research in our laboratories, clinics and multiethnic and multicultural communities that builds upon our unique scientific and regional strengths; 2) reduce the burden of cancer incidence and mortality by discovering the genetic, environmental, social, and behavioral factors that contribute to the distinct cancer patterns and cancer disparities in the peoples of the American Southwest; 3) translate our scientific discoveries to novel diagnostic, screening, prevention, and therapeutic tools and clinical trials; and 4) provide access to outstanding cancer treatment and clinical trials for all New Mexicans.